Literature DB >> 28416558

In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model.

M L Monogue1, L M Abbo2,3, R Rosa3, J F Camargo2, O Martinez4, R A Bonomo5,6, D P Nicolau7,8.   

Abstract

The management of infections with New Delhi metallo-beta-lactamase-1 (NDM)-producing bacteria remains clinically challenging given the multidrug resistant (MDR) phenotype associated with these bacteria. Despite resistance in vitro, ceftazidime-avibactam previously demonstrated in vivo activity against NDM-positive Enterobacteriaceae Herein, we observed in vitro synergy with ceftazidime-avibactam and aztreonam against an MDR Klebsiella pneumoniae harboring NDM. In vivo, humanized doses of ceftazidime-avibactam monotherapy resulted in >2 log10 CFU bacterial reduction; therefore, no in vivo synergy was observed.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Klebsiella pneumoniae; New Delhi metallo-β-lactamase; ceftazidime-avibactam; resistance

Mesh：

Substances：

Year:  2017        PMID： 28416558      PMCID： PMC5487677          DOI： 10.1128/AAC.00486-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

2.  Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Jiancheng Zhang; Sunil Maharjan; Michel Doumith; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

3.  Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

4.  The fractional inhibitory concentration (FIC) index as a measure of synergy.

Authors:  M J Hall; R F Middleton; D Westmacott
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

5.  Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

Authors:  P R S Lagacé-Wiens; F Tailor; P Simner; M DeCorby; J A Karlowsky; A Walkty; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

6.  Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Authors:  Steven Marshall; Andrea M Hujer; Laura J Rojas; Krisztina M Papp-Wallace; Romney M Humphries; Brad Spellberg; Kristine M Hujer; Emma K Marshall; Susan D Rudin; Federico Perez; Brigid M Wilson; Ronald B Wasserman; Linda Chikowski; David L Paterson; Alejandro J Vila; David van Duin; Barry N Kreiswirth; Henry F Chambers; Vance G Fowler; Michael R Jacobs; Mark E Pulse; William J Weiss; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

7.  Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Authors:  Brent W Gunderson; Khalid H Ibrahim; Laurie B Hovde; Timothy L Fromm; Michael D Reed; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.

Authors:  Roy F Chemaly; Santosh S Hanmod; Ying Jiang; Dhanesh B Rathod; Victor Mulanovich; Javier A Adachi; Kenneth V Rolston; Issam I Raad; Ray Y Hachem
Journal:  Medicine (Baltimore)       Date:  2009-07       Impact factor: 1.889

9.  Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.

Authors:  Jared L Crandon; Virna J Schuck; Mary Anne Banevicius; Marie-Eve Beaudoin; Wright W Nichols; M Angela Tanudra; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

10.  Tigecycline displays in vivo bactericidal activity against extended-spectrum-β-lactamase-producing Enterobacteriaceae after 72-hour exposure period.

Authors:  Pamela R Tessier; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191
View more
  12 in total

1.  Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Benjamin Davido; Lesly Fellous; Christine Lawrence; Virginie Maxime; Martin Rottman; Aurélien Dinh
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Analysis of Paradoxical Efficacy of Carbapenems against Carbapenemase-Producing Escherichia coli in a Murine Model of Lethal Peritonitis.

Authors:  Ariane Roujansky; Victoire de Lastours; François Guérin; Françoise Chau; Geoffrey Cheminet; Laurent Massias; Vincent Cattoir; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

Review 3.  Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.

Authors:  Sara E Boyd; David M Livermore; David C Hooper; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

4.  Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.

Authors:  M Biagi; T Wu; M Lee; S Patel; D Butler; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

Review 5.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

6.  Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.

Authors:  Sean M Stainton; Kamilia Abdelraouf; Luke Utley; Michael J Pucci; Troy Lister; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 7.  NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.

Authors:  Wenjing Wu; Yu Feng; Guangmin Tang; Fu Qiao; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

Review 8.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

9.  Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.

Authors:  Shampa Das; Adam Johnson; Laura McEntee; Nicola Farrington; Adam Kirby; Jennifer Unsworth; Ana Jimenez-Valverde; Ruwanthi Kolamunnage-Dona; Justine Bousquet; Laethitia Alibaud; Carole Sable; Magdalena Zalacain; Martin Everett; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  Extensively drug-resistant (XDR) Pseudomonas aeruginosa identified in Lima, Peru co-expressing a VIM-2 metallo-β-lactamase, OXA-1 β-lactamase and GES-1 extended-spectrum β-lactamase.

Authors:  Paul Ríos; Claudio Rocha; William Castro; Maria Vidal; Enrique Canal; Manuela Bernal; Nathanael D Reynolds; Drake H Tilley; Mark P Simons
Journal:  JMM Case Rep       Date:  2018-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.